Periorificial dermatitis

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Periorificial dermatitis is a clinical pattern of small inflammatory lesions around facial openings, historically called perioral dermatitis. It affects adults and children of any sex or skin tone. Erythema may be pink, red, violaceous, grey-brown or barely visible; the more dependable findings are grouped raised lesions, surface dryness, burning or tightness and characteristic distribution with relative vermilion-border sparing.

The treatment history is often diagnostic. Ask the patient to bring or photograph every facial cream, cosmetic, toothpaste, inhaler and nasal spray, and clarify transfer from hands treating another body site. A steroid may seem effective for days because it suppresses inflammation, then drive rebound when omitted. Explain this cycle before withdrawal so a predictable early flare is not mistaken for proof that the steroid is needed.

Management minimises exposure while respecting necessary therapies and patient priorities. Simplified care alone may be sufficient but improvement can take weeks. Topical metronidazole or pimecrolimus is used off label in selected mild disease; an oral tetracycline is a common off-label option for more extensive disease. Recurrent, granulomatous, scarring, periocular or treatment-resistant presentations deserve dermatology review and sometimes biopsy.

Key points

Look for grouped 1–2 mm papules, papulovesicles or pustules around mouth, nose or eyes, often with dry sensitive skin and a narrow spared strip beside the lip vermilion.
Absence of comedones helps separate periorificial dermatitis from acne; persistent diffuse centrofacial flushing and telangiectasia favour rosacea.
Ask specifically about prescribed, borrowed and over-the-counter topical corticosteroids, transfer from hands, inhalers, nasal sprays, cosmetics and heavy facial products.
Stop an unnecessary facial topical corticosteroid with an explained plan; warn that the eruption can flare temporarily after withdrawal and do not restart reflexively.
Do not stop an essential inhaled or intranasal corticosteroid without controlling the airway indication; optimise technique, use a spacer when appropriate and clean exposed facial skin.
Simplify skin care temporarily to lukewarm water or a gentle non-soap cleanser and a light tolerated product, then reintroduce necessities one at a time.
Mild local disease can use a topical option off label; more extensive disease often responds to an off-label oral tetracycline for a defined four-to-six-week course.
In children, pregnancy or breastfeeding, tetracycline treatment is unsuitable and alternative management should be selected with age- and pregnancy-specific expertise.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Topical corticosteroid exposure

Direct facial use is the strongest practical association; transfer from treated hands and exposure to inhaled or intranasal corticosteroids can also contribute.

Occlusive product burden

Heavy moisturisers, cosmetics, fragranced cleansers and some sunscreens can alter the barrier and follicular environment in a susceptible person.

Idiopathic susceptibility

No single cause is found in many cases, and proposed microbial or hormonal contributors do not justify routine cultures or endocrine testing.

Physical aggravation

Ultraviolet exposure, heat and wind may worsen burning or papules but are modifiers rather than proof of a particular underlying mechanism.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Barrier disruption
Corticosteroids and multiple facial products can disturb epidermal barrier and innate immune signalling, producing sensitive inflamed skin around facial orifices.
2
Follicular papular inflammation
Small inflammatory papules, papulovesicles and pustules cluster around follicles but usually do not form the open or closed comedones of acne.
3
Steroid suppression and rebound
A corticosteroid may transiently flatten lesions, then provoke worse inflammation when reduced, reinforcing repeated application and delaying durable resolution.
4
Periorificial extension
The process can involve perioral, perinasal and periocular skin while characteristically sparing a narrow zone immediately beside the lip vermilion.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Perioral papular ring

Monomorphic small papules and occasional pustules cluster around the mouth while a narrow band immediately adjoining the lip edge remains clear.

Perinasal or periocular extension

Similar lesions beside nostrils or around eyelids support the broader term periorificial dermatitis and require careful eye-symptom enquiry.

Sensitive dry surface

Burning, tightness and fine scale are common; itch may occur but usually does not dominate as strongly as in allergic contact dermatitis.

Steroid-linked rebound

Temporary clearing after facial corticosteroid application followed by a sharper flare when stopped is a characteristic self-perpetuating history.

Comedone absence

Careful inspection finds neither blackheads nor whiteheads, helping distinguish the eruption from acne despite superficial pustules.

Ocular warning departureRed flag

Eye pain, photophobia, reduced vision or corneal abnormality is not uncomplicated periocular skin disease and needs urgent ophthalmic assessment.

Red flags requiring action

Eye pain, photophobia or reduced vision; honey-coloured crust with spreading infection; vesicles with ocular proximity; rapid facial swelling; fever; scarring; or a fixed photosensitive or granulomatous eruption requires urgent or specialist diagnostic review.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Complete topical and inhaled exposure inventoryFirst step
Why
Find direct, transferred and aerosolised corticosteroid exposure and other potentially aggravating products.
Interpretation and limitations
Record exact product, potency, site, duration and response; necessary airway therapy is optimised rather than stopped without an alternative plan.
02
Morphology and distribution examination
Why
Confirm the periorificial pattern and look for comedones, telangiectasia, crust, vesicles or scale suggesting a mimic.
Interpretation and limitations
Vermilion sparing supports but is not mandatory; colour alone is unreliable across skin tones, so palpate and assess surface change.
03
Bacterial or viral swab when indicated
Why
Investigate impetigo, bacterial folliculitis or herpes when crust, erosion or grouped vesicles is present.
Interpretation and limitations
Sample a fresh lesion before antimicrobials where safe; routine swabbing of typical dry papules has low diagnostic yield.
04
Skin scraping or fungal study
Why
Assess a scaly annular or otherwise atypical eruption for fungal infection.
Interpretation and limitations
Choose the active untreated edge and state prior steroid exposure because corticosteroids can distort tinea morphology.
05
Punch biopsy for persistent atypical disease
Why
Evaluate granulomatous, scarring or treatment-resistant lesions for inflammatory and infiltrative mimics.
Interpretation and limitations
Obtain informed consent, choose a representative lesion, agree handling with histopathology and provide the full differential and treatment history.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Acne vulgaris

Comedones, polymorphic lesions and wider facial or truncal distribution support acne, whereas periorificial dermatitis consists mainly of small grouped papules.

Rosacea

Persistent centrofacial erythema, flushing, telangiectasia and ocular rosacea favour rosacea; overlap is possible and morphology should determine treatment.

Contact dermatitis

Prominent itch, diffuse scale, sharp product distribution or exposure to flavouring, fragrance or cosmetics supports irritant or allergic contact dermatitis.

Impetigo or herpes simplex

Honey-coloured crust and spreading erosion suggest impetigo, while grouped painful vesicles and punched-out erosions suggest herpes and change sampling and urgency.

Granulomatous or connective-tissue disease

Firm monomorphic papules, scarring, dyspigmentation, photosensitivity or systemic features justify biopsy or targeted investigation for sarcoid, lupus and other mimics.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01Exposure withdrawalBreak the corticosteroid cycleFirst stepTypical periorificial lesions occur during direct or indirect facial corticosteroid exposure.

1Explain the association and possible temporary rebound, then stop an unnecessary facial corticosteroid; a supervised short taper with low-potency treatment is reserved for selected prolonged misuse rather than automatic continuation.
2Retain essential inhaled or intranasal treatment, coordinate with its prescriber, optimise device or spacer technique and wash or rinse exposed perioral skin after use.
3Temporarily simplify cosmetics, fragranced cleansers and heavy occlusive products, using a light tolerated moisturiser only when necessary, and review evolution over the next weeks.

02Mild local diseaseAdd a low-burden topical optionDisease is limited, there are no urgent mimics and withdrawal measures alone are insufficient or unacceptable.

1Discuss that topical metronidazole or pimecrolimus use is off label for this diagnosis, choose one product and set realistic expectations for a slow response.
2Apply a thin layer away from eyes and mucosa, reduce frequency if irritation develops and avoid layering multiple new active products.
3Review at four to six weeks for lesion reduction, adherence and diagnostic fit; stop ineffective exposure and investigate or refer rather than adding indefinite topical antibiotics.

03Extensive or persistent diseaseUse a defined systemic coursePapules are widespread, distressing or inadequately controlled with exposure withdrawal and suitable topical care.

1Check pregnancy, breastfeeding, age, allergy, interactions and organ factors, then discuss off-label oral tetracycline treatment.
2Use doxycycline 100 mg once daily or lymecycline 408 mg once daily for four to six weeks with safe administration and photosensitivity counselling.
3Stop after the defined response course, maintain simplified skin care and refer recurrent, scarring, granulomatous or non-responsive disease for diagnostic review.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

An off-label topical anti-inflammatory option for limited periorificial dermatitis when withdrawal and simplified care need additional treatment.

Metronidazole 0.75% cream

Apply a thin layer to affected periorificial skin twice daily for a planned four-to-six-week trial, keeping it out of the eyes, lips and mucosa.

Explain off-label status, reduce or stop for significant irritation, avoid ocular contact and reconsider the diagnosis rather than extending indefinitely without improvement.

An off-label oral anti-inflammatory tetracycline option for extensive or persistent periorificial dermatitis in an appropriate adult.

Lymecycline 408 mg capsules

Take one capsule orally once daily for a defined four-to-six-week off-label course when systemic treatment is indicated.

Avoid pregnancy, breastfeeding and children under 12; consider hepatic or renal disease, photosensitivity, intracranial-pressure symptoms and interactions, and never combine with isotretinoin.

An alternative finite systemic option when inflammatory disease is too extensive for topical treatment alone.

Doxycycline 100 mg capsules

Take 100 mg orally once daily for four to six weeks off label, swallowed with plenty of water while upright and according to product-specific food directions.

Unsuitable in pregnancy, breastfeeding and under 12 years; warn about oesophagitis and photosensitivity, review mineral or antacid interactions and avoid isotretinoin overlap.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Persistent relapsing disease

Reintroduction of a facial corticosteroid or the same occlusive product can restart inflammation after an initially successful course.

Steroid skin damage

Prolonged facial corticosteroid use can add atrophy, telangiectasia, easy bruising and rebound, making the eruption more difficult to interpret.

Pigmentary change

Inflamed papules or irritant treatment can leave prolonged hyperpigmentation or hypopigmentation, particularly when inflammation is under-recognised in darker skin.

Psychosocial impact

A conspicuous facial eruption, uncertainty about safe products and an initial withdrawal flare can impair confidence, work, relationships and adherence.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Review within four to six weeks, comparing papule number and distribution, burning, scale, product burden and whether the corticosteroid rebound has begun to settle.
Ask whether an inhaler, nasal spray, hand-applied steroid or cosmetic was reintroduced inadvertently before labelling the condition treatment resistant.
During systemic treatment, monitor swallowing pain, photosensitivity, severe headache or visual symptoms, diarrhoea, rash and changes in pregnancy status.
Use consented, securely stored photographs with consistent lighting when pigment change obscures lesion activity, and distinguish flat residual colour from new raised papules.
Safety-net ocular pain, photophobia, vision change, spreading crusted infection, vesicles, fever, scarring or systemic symptoms for earlier review.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

The lip edge clue

A narrow unaffected strip beside the vermilion is characteristic and helps separate the eruption from lip-licking or contact dermatitis.

Improvement can initially look worse

A withdrawal flare after stopping facial corticosteroid exposure is expected in some patients and should be anticipated before it undermines confidence.

Indirect steroid exposure counts

Hands, aerosol plumes and nasal-spray runoff can deliver corticosteroid to periorificial skin even when no facial cream is prescribed.

Zero therapy is temporary simplification

Reducing products helps identify drivers and calm the barrier; necessary photoprotection and airway medicines still need individual safe solutions.

Raised lesions define activity

Flat hyperpigmented macules may remain after control and should not automatically trigger another antibiotic course.

11Common pitfallsFrequent interpretation and management errors.

01
Restarting a potent facial corticosteroid during the predictable rebound and perpetuating the suppression-flare cycle.
02
Stopping a necessary asthma preventer without coordinating equivalent airway control because an inhaled steroid may contribute.
03
Calling every perioral eruption acne and overlooking vermilion sparing, absent comedones and topical-steroid exposure.
04
Applying several active products at once so irritancy obscures whether the underlying dermatitis is improving.
05
Using a prolonged oral antibiotic to treat flat pigment after the inflammatory papules have resolved.